Navigation Links
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
Date:5/21/2008

PHILLIPSBURG, N.J., May 21 /PRNewswire/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics, Nasdaq: AVAN) announced today it has received Federal Trade Commission approval under the Hart-Scott Rodino (HSR) Act, clearing AVANT's proposal to award Pfizer (NYSE: PFE) exclusive rights to CDX-110, an investigational vaccine currently under development.

On April 16, 2008, Pfizer, Inc. and Celldex announced that they entered into an agreement under which Pfizer would be granted an exclusive worldwide license to CDX-110, currently being evaluated in a Phase 2 study for the treatment of glioblastoma multiforme (GBM). The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications.

About CDX-110

CDX-110 is designed to induce or enhance the body's immune responses against EGFRvIII resulting in destruction of tumor cells that express the variant receptor. Single arm Phase 2 clinical trials of CDX-110 in combination with the current standard treatment for patients with GBM have been conducted. Updated clinical data will be released at the American Society for Clinical Oncology Meeting in Chicago on June 2, 2008. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics and Celldex Therapeutics combined during the first quarter of 2008. AVANT is a Nasdaq-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is exploiting its access to proprietary human antibody technology for development of therapeutic monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development. Identification of the potential of EGFRvIII in cancer diagnosis, prevention and therapy was based on the collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Application of this discovery toward the development of the CDX-110 vaccine was further advanced by Dr. John Sampson and his colleagues at the Duke University Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD Anderson Cancer Center. AVANT has several other product candidates in its development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting

Technology(TM), which is in two Phase 1 clinical trials for patients

with advanced pancreatic, bladder, breast and colon cancer;

-- TP10, a complement inhibitor, in development for transplantation and

other indications; and

-- Three candidates based on oral, rapidly-protecting, single-dose and

temperature-stable vaccine technology, including combination vaccines

for travellers, the military and global health needs.

AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through its web site http://www.avantimmune.com.

AVANT Immunotherapeutics, Inc.

Anthony S. Marucci, 781-433-0771

Interim President and CEO

BMC Communications

Marissa Nelson

(212) 477-9007 x21


'/>"/>
SOURCE Celldex Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avantium and BP Extend Strategic Partnership
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... thrilled to announce the ATA 2017 President’s Awards recipients, comprised of organizations ... superior healthcare delivery. , The ATA 2017 President’s Awards recognize individuals ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Excellence specializes in pelvic conditions and has helped many women become pregnant upon ... a combination of office-based and simple outpatient evaluations. We can provide the ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for sponsors and CROs to speed clinical development, has released the industry’s ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: